
Roche Pharmaceuticals has announced that Fortovase® brand saquinavir capsules will ... Full Alert
Saquinavir is used in combination with other medications to treat human immunodeficiency virus (HIV) infection in patients with or without acquired immunodeficiency syndrome (AIDS). Saquinavir is in a class of antiviral medications called protease inhibitors. It works by slowing the spread of HIV in the body. Saquinavir does not cure HIV and may not prevent you from developing HIV-related illnesses. Saquinavir does not prevent the spread of HIV to other people.
Saquinavir comes as a hard gelatin capsule (Invirase), a tablet (Invirase), and a soft gelatin capsule (Fortovase) to take by mouth. The hard gelatin capsule and tablet are usually taken with ritonavir (Norvir) two times a day with a meal or up to 2 hours after a full meal. The soft gelatin capsule is usually taken three times a day with a meal or up to 2 hours after a meal. Take saquinavir at around the same times every day. It may be easier to remember to take saquinavir if you take it with meals. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take saquinavir exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Continue to take saquinavir even if you feel well. Do not stop taking saquinavir without talking to your doctor. If you miss doses, take less than the prescribed dose or stop taking saquinavir, your condition may become more difficult to treat.
Saquinavir soft gelatin capsules are also used to help prevent infection in health care workers or other people who were accidentally exposed to HIV. Talk to your doctor about the possible risks of using this medication for your condition.
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
©2009. All Rights Reserved.
Your use of this information is subject to our User Agreement available at www.ConsumerReportsHealth.org.














